Cereno Scientific appoints Dr. Rahul Agrawal as Chief Medical Officer and Head of R&D
Cereno Scientific (Nasdaq First North: CRNO B) today announced that Dr. Rahul Agrawal has been appointed as Chief Medical Officer and Head of R&D. The recruitment follows an intense period in the clinical-stage biotech’s growth journey. Cereno is focused on developing innovative treatments for common and rare cardiovascular disease, with lead candidate drug CS1 currently in phase II for the orphan disease pulmonary arterial hypertension (PAH). On January 30th CS1 received FDA approval for Expanded Access also known as “Compassionate Use” after Cereno had received request to apply for CU from